<div id="readability-page-1"><p>Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immuneering today and set a price target of $20.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Tenaya Therapeutics. According to TipRanks, Livshits has an average return of <span>7.8%</span> and a 35.98% success rate on recommended stocks. </p> <p>In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $12.00 price target.</p></div>

IMRX

LABU

ARKG

<p>Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00. Livshits, who focuses on the Healthcare sector, has an average return of 7.8% and a 35.98% success rate on recommended stocks. Mizuho Securities also maintained a Buy rating on the stock, setting a price target of $12.00.</p>

Tip Ranks

Immuneering

VG Health

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

iShares Biotechnology ETF

Palvella Therapeutics

Iovance Biotherapeautics

Tenaya Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

Immuneering (IMRX) Gets a Buy from Chardan Capital